In Vitro and Animal Models for Emerging Infectious Diseases and Biodefense

新发传染病和生物防御的体外和动物模型

• 批准号: 7697212
• 金额: $ 121.44万
• 依托单位: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/7697212
• 关键词: Vitro; Animal; Models; Emerging; Infectious

The In Vitro and Animal Models for Emerging Diseases and Biodefense contract provides the development and standardization of small animal and non-human primate models, and may include efficacy testing of vaccines and/or therapeutics, including GLP studies to support product licensure. Vaccines and therapeutics which are efficacious in small animals may be further tested in non-human primate models. This contract also provides testing of vaccines for safety and immunogenicity, to include humoral and cellular immunity, in small animals as well as non-human primates, under GLP where appropriate. In addition, it can perform testing of therapeutics for safety and pharmacology, in small animals as well as non-human primates, under GLP where appropriate.

用于新兴疾病和生物形式合同的体外和动物模型提供了小动物和非人类灵长类动物模型的开发和标准化，并可能包括疫苗和/或治疗剂的功效测试，包括GLP研究以支持产品许可。在非人类灵长类动物模型中，可以进一步测试在小动物中有效的疫苗和治疗剂。该合同还提供了针对安全性和免疫原性的疫苗测试，包括小动物以及非人类灵长类动物的体液和细胞免疫，在适当的情况下在GLP下进行。此外，在适当的情况下，它可以在小动物以及非人类灵长类动物的安全和药理学，在适当的情况下对治疗剂进行安全和药理学的测试。